Clindesse is a prescription brand of clindamycin phosphate vaginal cream 2% supplied as a single-dose prefilled applicator. Its product identity is important because a 2% concentration appears on other vaginal creams that have different packaging and directions. Clindesse is a named formulation, not a shorthand for all vaginal clindamycin creams.
The U.S. label describes treatment of bacterial vaginosis in nonpregnant women and specifies one prefilled applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin. The product is for intravaginal use only. For the direct comparison with the conventional branded multi-application product, see Clindesse vs Cleocin vaginal cream.
A patient or pharmacist should verify the exact brand, prefilled applicator, intravaginal route and the product’s five-day barrier-method warning before dispensing. The U.S. label also lists formal contraindications involving certain bowel diseases, prior C. difficile-associated diarrhea and clindamycin/lincosamide hypersensitivity. A drug database entry does not confirm local inventory or personal suitability.
Clindesse is a branded single-dose clindamycin phosphate 2% vaginal cream. It has one prefilled disposable applicator, whereas standard vaginal cream products may be supplied in a tube with multiple applicators for a different prescribed course.
The distinction concerns the complete formulation and labeled product, not simply clindamycin content. Use the vaginal cream form guide for the family-wide discussion; this page deals with Clindesse specifically.
| Product | Presentation | Key distinction |
|---|---|---|
| Clindesse | 2% cream; single prefilled applicator | Five-day latex/rubber warning |
| Cleocin vaginal cream | 2% cream; standard multi-application product | Different regimen; 72-hour latex/rubber warning |
| Xaciato | 2% vaginal gel; user-filled applicator | Polyurethane condom warning for seven days |
| Cleocin vaginal ovules | 100 mg suppositories | Solid dosage form; 72-hour latex/rubber warning |
| Oral clindamycin | Capsule or oral liquid | Not a vaginal product |
The Clindesse label describes a single applicator delivering about 5 g of cream with 100 mg of clindamycin. Unlike a loose tube where multiple applicators may be filled, the product is packaged as one complete dose-specific unit.
Patients should read the supplied package instructions and the clinician’s directions; this factual packaging description is not a recommendation for every patient with vaginal symptoms. The drug must not be used on skin, in the eyes or by mouth.
Clindesse is labeled for bacterial vaginosis in nonpregnant women. Symptoms resembling BV can also reflect other causes, so clinical evaluation matters before choosing antibiotics. Its labeled population and specific warnings should not be generalized to other vaginal clindamycin products.
The BV clinical context page addresses assessment and alternatives while this brand page focuses on the specific product and dispensing identity.
Both products are clindamycin-containing vaginal creams at a nominal concentration of 2%, but Clindesse is a one-prefilled-applicator formulation and standard Cleocin cream has its own product label and regimen. The shared number 2% does not establish a safe swap.
The full product comparison belongs on the dedicated comparison page. Ask the clinician or pharmacist to verify any proposed change rather than substituting one branded product independently.
Xaciato is a single-dose clindamycin vaginal gel, not a cream. Its hydrogel vehicle, applicator design, labeled age range and condom warning differ from Clindesse. The term single-dose alone is therefore not enough to select the right product.
See the single-dose cream versus gel guide and the separate Xaciato brand dossier for product-specific distinctions.
The Clindesse cream contains mineral oil that may weaken latex or rubber condoms and vaginal diaphragms. Its U.S. label advises against using these barrier products concurrently or for five days after treatment because protection against pregnancy or infections may be unreliable.
This five-day Clindesse-specific guidance differs from the standard Cleocin vaginal cream and vaginal ovule 72-hour warnings. Ask the prescriber or pharmacist about an appropriate method of protection in the context of the actual dispensed medicine.
Clindesse counseling advises avoiding vaginal intercourse and additional vaginal products, such as tampons and douches, during treatment. Patients should review these restrictions before dispensing when contraception or concurrent vaginal therapy is relevant.
Because the product has a distinctive vehicle and applicator, instructions for a different vaginal gel or cream should never be copied from a general search result.
Clindesse labeling formally contraindicates use in people with hypersensitivity to clindamycin or other lincosamides and in people with regional enteritis, ulcerative colitis or a history of Clostridioides difficile-associated diarrhea. These are contraindications, not merely factors to mention after starting the medicine.
Vaginal use still involves some systemic absorption and carries a warning for severe antibiotic-associated diarrhea or colitis. New severe or persistent diarrhea, abdominal pain or signs of an allergic reaction require prompt medical assessment. See clindamycin contraindications for the route-specific framework.
Clindesse is a prescription drug. A licensed U.S. pharmacy should match the branded name, 2% vaginal cream, single prefilled applicator and patient directions. A description such as “clindamycin 2%” without the product form is incomplete.
For pharmacy legitimacy checks when ordering remotely, use online pharmacy verification. No pharmacy can be presumed to stock Clindesse merely because a label is published.
Generic vaginal clindamycin creams may exist, but a generic cream marketed for a different application schedule cannot be treated as a Clindesse equivalent on the strength percentage alone. Pharmacists must evaluate the complete product and prescription.
The generic clindamycin overview separates drug, route and vehicle identity. The clinician decides whether a different product is appropriate if the brand is unavailable.
Patient cost may depend on brand coverage, the one-applicator unit, formulary tier and the dispensing pharmacy. Comparing the shelf price of an unrelated multidose cream is not a like-for-like transaction.
Ask the pharmacy to verify the exact Clindesse product and current patient charge. Our vaginal-clindamycin cost guide covers evergreen factors without posting estimates that could go stale.
Verify the name Clindesse, 2% intravaginal cream, one prefilled applicator and the prescription’s instructions. Request clear counseling on the five-day barrier caution, vaginal-product restrictions, adverse reactions and when to contact a clinician.
If an alternate cream or gel appears on the receipt, ask the pharmacist to clarify the change. A labeled formulation, not a search keyword, determines the product the patient receives.
Clindesse is a branded 2% clindamycin phosphate vaginal cream supplied in one single-dose prefilled applicator.
Yes. Its U.S. label describes treatment of BV in nonpregnant women.
No. They have different branded formulations and labeled application frameworks.
No. Clindesse is a vaginal cream; Xaciato is a different clindamycin vaginal gel.
Yes. Its mineral-oil cream can weaken latex or rubber products; the label cautions against these barriers during treatment and for five days afterward.
No. It is a U.S. prescription-only product.
The label describes one approximately 5 g applicator of cream containing approximately 100 mg of clindamycin.
The U.S. Clindesse label lists a history of C. difficile-associated diarrhea as a formal contraindication. Discuss that history with the prescriber before any use.
No. Pharmacy stock and patient coverage require a separate current check.